AbbVie under pressure as schizophrenia drug fails two trials
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
AbbVie Reports Solid Q3 2024 Financial Performance
Abbvie ( (ABBV) ) has realeased its Q3 earnings. Here is a breakdown of the information Abbvie presented to its investors. AbbVie Inc. is a ...
Yahoo Finance13d
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario
VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...
The Victoria Advocate11d
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer EvolveImmune's ...
MedCity News14d
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...
Seeking Alpha11d
AbbVie Inc. (ABBV) Q3 2024 Earnings Call Transcript
Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only until the question-and-answer portion of ...
Morningstar11d
AbbVie, EvolveImmune Therapeutics Set Cancer Biotherapeutics Collaboration
AbbVie has inked a deal to work with privately held immuno-oncology company EvolveImmune Therapeutics, to develop therapeutic antibodies for cancer. AbbVie on Thursday said EvolveImmune will ...
Nasdaq10d
Is AbbVie (NYSE:ABBV) Stock a Buy After Its Dividend Hike?
Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...
Crain's Chicago Business11d
AbbVie Foundation's $75M gift will put its name on new UChicago cancer hospital
The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...
The University of Chicago Chronicle11d
$75 million donation from AbbVie Foundation to support UChicago Medicine’s new cancer pavilion
The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...
Crain's Chicago Business12d
Abbvie lifts profit outlook as inflammatory drugs Rinvoq and Skyrizi beat estimates
Gifting allows recipients to access the article for free. AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, exceeded ...